{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:00:12Z","timestamp":1792800012477,"version":"4.5.0"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Universiti Putra Malaysia through the Institutional Grant Scheme","award":["GP-IPM\/2021\/9700000"],"award-info":[{"award-number":["GP-IPM\/2021\/9700000"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12578-0","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T13:25:02Z","timestamp":1786627502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tau dysfunction in alzheimer\u2019s disease: molecular and cellular mechanisms, genetic modulation, and therapeutic perspectives"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5425-3634","authenticated-orcid":false,"given":"Sreenivasulu","family":"Sura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7389-7363","authenticated-orcid":false,"given":"Saravanan","family":"Jagadeesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9282-129X","authenticated-orcid":false,"given":"Mohamad Aris Mohd","family":"Moklas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4902-2935","authenticated-orcid":false,"given":"Siti Saleha","family":"Masrudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0812-1272","authenticated-orcid":false,"given":"Krishna Chaitanya Reddy","family":"Dandala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8521-4854","authenticated-orcid":false,"given":"John Paul","family":"Judson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8136-5604","authenticated-orcid":false,"given":"Nurul Huda","family":"MohdNor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"12578_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41419-025-08186-8","volume":"17","author":"AA Abdulkhaliq","year":"2026","unstructured":"Abdulkhaliq AA, Kim B, Almoghrabi YM et al (2026) Amyloid-\u03b2 and Tau in Alzheimer\u2019s disease: pathogenesis, mechanisms, and interplay. Cell Death Dis 17:21. https:\/\/doi.org\/10.1038\/s41419-025-08186-8","journal-title":"Cell Death Dis"},{"key":"12578_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.neuroscience.2025.10.050","volume":"590","author":"KS Vanya","year":"2025","unstructured":"Vanya KS, Bagri K, Deshmukh R (2025) Tangles and plaques: a deep dive into the pathological hallmarks of Alzheimer\u2019s disease. Neuroscience 590:170\u2013185. https:\/\/doi.org\/10.1016\/j.neuroscience.2025.10.050","journal-title":"Neuroscience"},{"key":"12578_CR3","doi-asserted-by":"publisher","first-page":"e70046","DOI":"10.1002\/jnr.70046","volume":"103","author":"S Kelliny","year":"2025","unstructured":"Kelliny S, Zhou XF, Bobrovskaya L (2025) Alzheimer\u2019s disease and frontotemporal dementia: a review of pathophysiology and therapeutic approaches. J Neurosci Res 103:e70046. https:\/\/doi.org\/10.1002\/jnr.70046","journal-title":"J Neurosci Res"},{"key":"12578_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14:535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers Dement"},{"key":"12578_CR5","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG et al (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement 20:5143\u20135169. https:\/\/doi.org\/10.1002\/alz.13859","journal-title":"Alzheimers Dement"},{"key":"12578_CR6","doi-asserted-by":"publisher","first-page":"15383","DOI":"10.3390\/ijms232315383","volume":"23","author":"A Corsi","year":"2022","unstructured":"Corsi A, Bombieri C, Valenti MT, Romanelli MG (2022) Tau isoforms: gaining insight into MAPT alternative splicing. Int J Mol Sci 23:15383. https:\/\/doi.org\/10.3390\/ijms232315383","journal-title":"Int J Mol Sci"},{"key":"12578_CR7","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1038\/s41467-022-30585-0","volume":"13","author":"AJ Dregni","year":"2022","unstructured":"Dregni AJ, Duan P, Xu H et al (2022) Fluent molecular mixing of Tau isoforms in Alzheimer\u2019s disease neurofibrillary tangles. Nat Commun 13:2967. https:\/\/doi.org\/10.1038\/s41467-022-30585-0","journal-title":"Nat Commun"},{"key":"12578_CR8","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1002\/alz.13784","volume":"20","author":"S Buchholz","year":"2024","unstructured":"Buchholz S, Zempel H (2024) The six brain-specific TAU isoforms and their role in Alzheimer\u2019s disease and related neurodegenerative dementia syndromes. Alzheimers Dement 20:3606\u20133628. https:\/\/doi.org\/10.1002\/alz.13784","journal-title":"Alzheimers Dement"},{"key":"12578_CR9","doi-asserted-by":"publisher","first-page":"e14403","DOI":"10.1002\/alz.14403","volume":"21","author":"S Buchholz","year":"2025","unstructured":"Buchholz S, Kabbani MAA, Bell-Simons M et al (2025) The tau isoform 1N4R confers vulnerability of MAPT knockout human iPSC-derived neurons to amyloid beta and phosphorylated tau-induced neuronal dysfunction. Alzheimers Dement 21:e14403. https:\/\/doi.org\/10.1002\/alz.14403","journal-title":"Alzheimers Dement"},{"key":"12578_CR10","doi-asserted-by":"publisher","first-page":"595532","DOI":"10.3389\/fneur.2020.595532","volume":"11","author":"C Alquezar","year":"2021","unstructured":"Alquezar C, Arya S, Kao AW (2021) Tau post-translational modifications: dynamic transformers of tau function, degradation, and aggregation. Front Neurol 11:595532. https:\/\/doi.org\/10.3389\/fneur.2020.595532","journal-title":"Front Neurol"},{"key":"12578_CR11","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1007\/s12035-023-03867-x","volume":"61","author":"J Yang","year":"2024","unstructured":"Yang J, Liu C, Dai J et al (2024) Complicated role of post-translational modification and proteolysis of tau in Alzheimer\u2019s disease and other tauopathies. Mol Neurobiol 61:3378\u20133403. https:\/\/doi.org\/10.1007\/s12035-023-03867-x","journal-title":"Mol Neurobiol"},{"key":"12578_CR12","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/biom15060824","volume":"15","author":"X Hong","year":"2025","unstructured":"Hong X, Huang L, Lei F, Li T, Luo Y, Zeng M, Wang Z (2025) The role and pathogenesis of tau protein in Alzheimer\u2019s disease. Biomolecules 15:824. https:\/\/doi.org\/10.3390\/biom15060824","journal-title":"Biomolecules"},{"key":"12578_CR13","doi-asserted-by":"publisher","first-page":"1551273","DOI":"10.3389\/fneur.2025.1551273","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Li Y, Luo X, Yang B et al (2025) New progress on the role and mechanism of tau protein in Alzheimer\u2019s disease and depression. Front Neurol 16:1551273. https:\/\/doi.org\/10.3389\/fneur.2025.1551273","journal-title":"Front Neurol"},{"key":"12578_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13024-025-00843-y","volume":"20","author":"AA Belaidi","year":"2025","unstructured":"Belaidi AA, Gunn-Moore FJ, Ghavami S, Simpson JE, Wharton SB (2025) Apolipoprotein E in Alzheimer\u2019s disease: molecular insights and therapeutic strategies. Mol Neurodegener 20:34. https:\/\/doi.org\/10.1186\/s13024-025-00843-y","journal-title":"Mol Neurodegener"},{"key":"12578_CR15","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle BW, Grenier-Boley B, Sims R et al (2019) Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet 51:414\u2013430. https:\/\/doi.org\/10.1038\/s41588-019-0358-2","journal-title":"Nat Genet"},{"key":"12578_CR16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","volume":"54","author":"C Bellenguez","year":"2022","unstructured":"Bellenguez C, Kucukali F, Jansen IE et al (2022) New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias. Nat Genet 54:412\u2013436. https:\/\/doi.org\/10.1038\/s41588-022-01024-z","journal-title":"Nat Genet"},{"key":"12578_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12031-016-0715-x","volume":"58","author":"YI Pachima","year":"2016","unstructured":"Pachima YI, Zhou LY, Lei P, Gozes I (2016) Microtubule-tau interaction as a therapeutic target for Alzheimer\u2019s disease. J Mol Neurosci 58:145\u2013152. https:\/\/doi.org\/10.1007\/s12031-016-0715-x","journal-title":"J Mol Neurosci"},{"key":"12578_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13195-025-01775-x","volume":"17","author":"GA Harris","year":"2025","unstructured":"Harris GA, Hirschfeld LR, Gonzalez MI, Pritchard MC, May PC (2025) Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials. Alzheimers Res Ther 17:129. https:\/\/doi.org\/10.1186\/s13195-025-01775-x","journal-title":"Alzheimers Res Ther"},{"key":"12578_CR19","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.3390\/cells14191506","volume":"14","author":"X Shen","year":"2025","unstructured":"Shen X, Li H, Zhang B, Li Y, Zhu Z (2025) Tau-targeted therapeutic strategies: mechanistic targets, clinical pipelines, and analysis of failures. Cells 14:1506. https:\/\/doi.org\/10.3390\/cells14191506","journal-title":"Cells"},{"key":"12578_CR20","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s12031-018-1174-3","volume":"66","author":"NV Gorantla","year":"2018","unstructured":"Gorantla NV, Chinnathambi S (2018) Tau protein squired by molecular chaperones during Alzheimer\u2019s disease. J Mol Neurosci 66:356\u2013368. https:\/\/doi.org\/10.1007\/s12031-018-1174-3","journal-title":"J Mol Neurosci"},{"key":"12578_CR21","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s12031-018-1111-5","volume":"65","author":"SK Sonawane","year":"2018","unstructured":"Sonawane SK, Chinnathambi S (2018) Prion-like propagation of post-translationally modified tau in Alzheimer\u2019s disease: a hypothesis. J Mol Neurosci 65:480\u2013490. https:\/\/doi.org\/10.1007\/s12031-018-1111-5","journal-title":"J Mol Neurosci"},{"key":"12578_CR22","doi-asserted-by":"publisher","first-page":"e70048","DOI":"10.1002\/alz.70048","volume":"21","author":"L Wang","year":"2025","unstructured":"Wang L, Sooram B, Kumar R, Schedin-Weiss S, Winblad B (2025) Tau degradation in Alzheimer\u2019s disease: mechanisms and therapeutic opportunities. Alzheimers Dement 21:e70048. https:\/\/doi.org\/10.1002\/alz.70048","journal-title":"Alzheimers Dement"},{"key":"12578_CR23","doi-asserted-by":"publisher","first-page":"e70165","DOI":"10.1002\/trc2.70165","volume":"11","author":"B Frost","year":"2025","unstructured":"Frost B, Kolb H, Algeciras-Schimnich A et al (2025) Tau biology, biomarkers, and therapeutics. Alzheimers Dement (N Y) 11:e70165. https:\/\/doi.org\/10.1002\/trc2.70165","journal-title":"Alzheimers Dement (N Y)"},{"key":"12578_CR24","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.3390\/biomedicines12051097","volume":"12","author":"M Hassan","year":"2024","unstructured":"Hassan M, Yasir M, Shahzadi S et al (2024) Molecular role of protein phosphatases in Alzheimer\u2019s and other neurodegenerative diseases. Biomedicines 12:1097. https:\/\/doi.org\/10.3390\/biomedicines12051097","journal-title":"Biomedicines"},{"key":"12578_CR25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s11011-026-01894-w","volume":"41","author":"S Sura","year":"2026","unstructured":"Sura S, Jagadeesan S, Okwuofu EO et al (2026) Cannabidiol attenuates tau hyperphosphorylation and cognitive deficits in an experimental model of Alzheimer\u2019s disease and is associated with restoration of PP2A expression. Metab Brain Dis 41:124. https:\/\/doi.org\/10.1007\/s11011-026-01894-w","journal-title":"Metab Brain Dis"},{"key":"12578_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.conb.2021.03.003","volume":"69","author":"S Wegmann","year":"2021","unstructured":"Wegmann S, Biernat J, Mandelkow E (2021) A current view on tau protein phosphorylation in Alzheimer\u2019s disease. Curr Opin Neurobiol 69:131\u2013138. https:\/\/doi.org\/10.1016\/j.conb.2021.03.003","journal-title":"Curr Opin Neurobiol"},{"key":"12578_CR27","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s12031-022-02002-0","volume":"72","author":"H Ye","year":"2022","unstructured":"Ye H, Han Y, Li P, Su Z, Huang Y (2022) The role of post-translational modifications on the structure and function of tau protein. J Mol Neurosci 72:1557\u20131571. https:\/\/doi.org\/10.1007\/s12031-022-02002-0","journal-title":"J Mol Neurosci"},{"key":"12578_CR28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","volume":"164","author":"B De Strooper","year":"2016","unstructured":"De Strooper B, Karran E (2016) The cellular phase of Alzheimer\u2019s disease. Cell 164:603\u2013615. https:\/\/doi.org\/10.1016\/j.cell.2015.12.056","journal-title":"Cell"},{"key":"12578_CR29","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1146\/annurev-pathmechdis-051222-120750","volume":"19","author":"BC Creekmore","year":"2024","unstructured":"Creekmore BC, Watanabe R, Lee EB (2024) Neurodegenerative disease tauopathies. Annu Rev Pathol 19:345\u2013370. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-051222-120750","journal-title":"Annu Rev Pathol"},{"key":"12578_CR30","doi-asserted-by":"publisher","first-page":"106942","DOI":"10.1016\/j.nbd.2025.106942","volume":"211","author":"B Spencer","year":"2025","unstructured":"Spencer B, Schueler A, Sung D, Rissman RA et al (2025) Differential roles of human tau isoforms in the modulation of inflammation and development of neuropathology. Neurobiol Dis 211:106942. https:\/\/doi.org\/10.1016\/j.nbd.2025.106942","journal-title":"Neurobiol Dis"},{"key":"12578_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40035-024-00429-6","volume":"13","author":"X Zhang","year":"2024","unstructured":"Zhang X, Wang J, Zhang Z, Ye K (2024) Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies. Transl Neurodegener 13:40. https:\/\/doi.org\/10.1186\/s40035-024-00429-6","journal-title":"Transl Neurodegener"},{"key":"12578_CR32","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1474-4422(13)70090-5","volume":"12","author":"MG Spillantini","year":"2013","unstructured":"Spillantini MG, Goedert M (2013) Tau pathology and neurodegeneration. Lancet Neurol 12:609\u2013622. https:\/\/doi.org\/10.1016\/S1474-4422(13)70090-5","journal-title":"Lancet Neurol"},{"key":"12578_CR33","doi-asserted-by":"publisher","first-page":"1255555","DOI":"10.1126\/science.1255555","volume":"349","author":"M Goedert","year":"2015","unstructured":"Goedert M (2015) Alzheimer\u2019s and Parkinson\u2019s diseases: the prion concept in relation to assembled Abeta, tau, and alpha-synuclein. Science 349:1255555. https:\/\/doi.org\/10.1126\/science.1255555","journal-title":"Science"},{"key":"12578_CR34","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature23002","volume":"547","author":"AWP Fitzpatrick","year":"2017","unstructured":"Fitzpatrick AWP, Falcon B, He S et al (2017) Cryo-EM structures of tau filaments from Alzheimer\u2019s disease. Nature 547:185\u2013190. https:\/\/doi.org\/10.1038\/nature23002","journal-title":"Nature"},{"key":"12578_CR35","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41591-020-0938-9","volume":"26","author":"S Dujardin","year":"2020","unstructured":"Dujardin S, Commins C, Lathuiliere A et al (2020) Tau molecular diversity contributes to clinical heterogeneity in Alzheimer\u2019s disease. Nat Med 26:1256\u20131263. https:\/\/doi.org\/10.1038\/s41591-020-0938-9","journal-title":"Nat Med"},{"key":"12578_CR36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41398-026-03947-1","volume":"16","author":"L Bakota","year":"2026","unstructured":"Bakota L, Tulva K, Trushina NI et al (2026) Beyond microtubule regulation: the multifaceted roles of tau in neuronal function and dysfunction. Transl Psychiatry 16:223. https:\/\/doi.org\/10.1038\/s41398-026-03947-1","journal-title":"Transl Psychiatry"},{"key":"12578_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nrneurol.2015.225","volume":"12","author":"K Iqbal","year":"2016","unstructured":"Iqbal K, Liu F, Gong CX (2016) Tau and neurodegenerative disease: the story so far. Nat Rev Neurol 12:15\u201327. https:\/\/doi.org\/10.1038\/nrneurol.2015.225","journal-title":"Nat Rev Neurol"},{"key":"12578_CR38","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/biom6010006","volume":"6","author":"G Simic","year":"2016","unstructured":"Simic G, Babic Leko M, Wray S et al (2016) Tau protein hyperphosphorylation and aggregation in Alzheimer\u2019s disease and other tauopathies, and possible neuroprotective strategies. Biomolecules 6:6. https:\/\/doi.org\/10.3390\/biom6010006","journal-title":"Biomolecules"},{"key":"12578_CR39","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s40478-023-01702-x","volume":"11","author":"N Younas","year":"2023","unstructured":"Younas N, Saleem T, Younas A, Zerr I (2023) Nuclear face of Tau: an inside player in neurodegeneration. Acta Neuropathol Commun 11:196. https:\/\/doi.org\/10.1186\/s40478-023-01702-x","journal-title":"Acta Neuropathol Commun"},{"key":"12578_CR40","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s42003-024-05920-4","volume":"7","author":"LS Abasi","year":"2024","unstructured":"Abasi LS, Elathram N, Movva M, Deep A, Corbett KD, Debelouchina GT (2024) Phosphorylation regulates tau\u2019s phase separation behavior and interactions with chromatin. Commun Biol 7:251. https:\/\/doi.org\/10.1038\/s42003-024-05920-4","journal-title":"Commun Biol"},{"key":"12578_CR41","doi-asserted-by":"publisher","first-page":"645233","DOI":"10.3389\/fncel.2021.645233","volume":"15","author":"RM Fleeman","year":"2021","unstructured":"Fleeman RM, Proctor EA (2021) Astrocytic propagation of tau in the context of Alzheimer\u2019s disease. Front Cell Neurosci 15:645233. https:\/\/doi.org\/10.3389\/fncel.2021.645233","journal-title":"Front Cell Neurosci"},{"key":"12578_CR42","doi-asserted-by":"publisher","first-page":"12841","DOI":"10.3390\/ijms232112841","volume":"23","author":"P Rawat","year":"2022","unstructured":"Rawat P, Sehar U, Bisht J, Selman A, Culberson J, Reddy PH (2022) Phosphorylated tau in Alzheimer\u2019s disease and other tauopathies. Int J Mol Sci 23:12841. https:\/\/doi.org\/10.3390\/ijms232112841","journal-title":"Int J Mol Sci"},{"key":"12578_CR43","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13024-025-00891-4","volume":"20","author":"YR Oh","year":"2025","unstructured":"Oh YR, Quintero-Rivera F, Abisambra JF (2025) Decoding tau acetylation in Alzheimer\u2019s disease and tauopathy. Mol Neurodegener 20:82. https:\/\/doi.org\/10.1186\/s13024-025-00891-4","journal-title":"Mol Neurodegener"},{"key":"12578_CR44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13024-024-00733-9","volume":"19","author":"C Parra Bravo","year":"2024","unstructured":"Parra Bravo C, Krukowski K, Barker S et al (2024) Anti-acetylated-tau immunotherapy is neuroprotective in tauopathy and brain injury. Mol Neurodegener 19:51. https:\/\/doi.org\/10.1186\/s13024-024-00733-9","journal-title":"Mol Neurodegener"},{"key":"12578_CR45","doi-asserted-by":"publisher","first-page":"e70320","DOI":"10.1002\/alz.70320","volume":"21","author":"E Fertan","year":"2025","unstructured":"Fertan E, Pratic\u00f2 D, Ossenkop KP et al (2025) Small-diffusible aggregates, plaques, tangles, and dynamic biomarkers in Alzheimer\u2019s disease. Alzheimers Dement 21:e70320. https:\/\/doi.org\/10.1002\/alz.70320","journal-title":"Alzheimers Dement"},{"key":"12578_CR46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s12031-020-01629-1","volume":"71","author":"Z Tang","year":"2021","unstructured":"Tang Z, Liang D, Cheng M, Su X, Liu R, Zhang Y, Wu H (2021) Effects of Porphyromonas gingivalis and its underlying mechanisms on Alzheimer-like tau hyperphosphorylation in Sprague-Dawley rats. J Mol Neurosci 71:89\u2013100. https:\/\/doi.org\/10.1007\/s12031-020-01629-1","journal-title":"J Mol Neurosci"},{"key":"12578_CR47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/JAD-170959","volume":"63","author":"JP Quinn","year":"2018","unstructured":"Quinn JP, Corbett NJ, Kellett KAB, Hooper NM (2018) Tau proteolysis in the pathogenesis of tauopathies: neurotoxic fragments and novel biomarkers. J Alzheimers Dis 63:13\u201333. https:\/\/doi.org\/10.3233\/JAD-170959","journal-title":"J Alzheimers Dis"},{"key":"12578_CR48","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/nm.3700","volume":"20","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Song M, Liu X et al (2014) Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer\u2019s disease. Nat Med 20:1254\u20131262. https:\/\/doi.org\/10.1038\/nm.3700","journal-title":"Nat Med"},{"key":"12578_CR49","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.4103\/1673-5374.385853","volume":"19","author":"D Chu","year":"2024","unstructured":"Chu D, Yang X, Wang J et al (2024) Tau truncation in the pathogenesis of Alzheimer\u2019s disease: a narrative review. Neural Regen Res 19:1221\u20131232. https:\/\/doi.org\/10.4103\/1673-5374.385853","journal-title":"Neural Regen Res"},{"key":"12578_CR50","doi-asserted-by":"publisher","first-page":"13812","DOI":"10.1074\/jbc.RA120.012587","volume":"295","author":"J Gu","year":"2020","unstructured":"Gu J, Xu W, Jin N et al (2020) Truncation of tau selectively facilitates its pathological activities. J Biol Chem 295:13812\u201313828. https:\/\/doi.org\/10.1074\/jbc.RA120.012587","journal-title":"J Biol Chem"},{"key":"12578_CR51","doi-asserted-by":"publisher","first-page":"1834737","DOI":"10.3389\/frdem.2026.1834737","volume":"5","author":"AJ Nordbeck","year":"2026","unstructured":"Nordbeck AJ, Sharma B, Garcia CA, Tseng J-H (2026) Post-translational modifications as a regulatory code for tau function in health and disease. Front Dement 5:1834737. https:\/\/doi.org\/10.3389\/frdem.2026.1834737","journal-title":"Front Dement"},{"key":"12578_CR52","doi-asserted-by":"publisher","first-page":"e70020","DOI":"10.1002\/trc2.70020","volume":"10","author":"W Kielbasa","year":"2024","unstructured":"Kielbasa W, Rogers T, Ashe K et al (2024) Discovery and clinical translation of ceperognastat, an O-GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer\u2019s disease. Alzheimers Dement (N Y) 10:e70020. https:\/\/doi.org\/10.1002\/trc2.70020","journal-title":"Alzheimers Dement (N Y)"},{"key":"12578_CR53","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1080\/13543776.2021.1947242","volume":"31","author":"JM Bartolome-Nebreda","year":"2021","unstructured":"Bartolome-Nebreda JM, Trabanco AA, Velter AI, Buijnsters P (2021) O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer\u2019s disease and related tauopathies: analysis of the patent literature. Expert Opin Ther Pat 31:1117\u20131154. https:\/\/doi.org\/10.1080\/13543776.2021.1947242","journal-title":"Expert Opin Ther Pat"},{"key":"12578_CR54","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.tins.2014.08.004","volume":"37","author":"H Zempel","year":"2014","unstructured":"Zempel H, Mandelkow E (2014) Lost after translation: missorting of tau protein and consequences for Alzheimer disease. Trends Neurosci 37:721\u2013732. https:\/\/doi.org\/10.1016\/j.tins.2014.08.004","journal-title":"Trends Neurosci"},{"key":"12578_CR55","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1016\/j.neuron.2023.04.020","volume":"111","author":"M Colom-Cadena","year":"2023","unstructured":"Colom-Cadena M, Davies C, Sirisi S et al (2023) Synaptic oligomeric tau in Alzheimer\u2019s disease \u2014 a potential culprit in the spread of tau pathology through the brain. Neuron 111:2170\u20132183e6. https:\/\/doi.org\/10.1016\/j.neuron.2023.04.020","journal-title":"Neuron"},{"key":"12578_CR56","doi-asserted-by":"publisher","first-page":"671779","DOI":"10.3389\/fnmol.2021.671779","volume":"14","author":"X Yin","year":"2021","unstructured":"Yin X, Jin N, Gu J et al (2021) Dendritic\/post-synaptic tau and early pathology of Alzheimer\u2019s disease. Front Mol Neurosci 14:671779. https:\/\/doi.org\/10.3389\/fnmol.2021.671779","journal-title":"Front Mol Neurosci"},{"key":"12578_CR57","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.ajpath.2017.03.011","volume":"187","author":"RE Bennett","year":"2017","unstructured":"Bennett RE, DeVos SL, Dujardin S et al (2017) Enhanced tau aggregation in the presence of amyloid beta. Am J Pathol 187:1601\u20131612. https:\/\/doi.org\/10.1016\/j.ajpath.2017.03.011","journal-title":"Am J Pathol"},{"key":"12578_CR58","doi-asserted-by":"publisher","first-page":"1219299","DOI":"10.3389\/fnins.2023.1219299","volume":"17","author":"D Lamontagne-Kam","year":"2023","unstructured":"Lamontagne-Kam D, Ulfat AK, Herv\u00e9 V et al (2023) Implication of tau propagation on neurodegeneration in Alzheimer\u2019s disease. Front Neurosci 17:1219299. https:\/\/doi.org\/10.3389\/fnins.2023.1219299","journal-title":"Front Neurosci"},{"key":"12578_CR59","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.neuron.2011.11.033","volume":"73","author":"A de Calignon","year":"2012","unstructured":"de Calignon A, Polydoro M, Suarez-Calvet M et al (2012) Propagation of tau pathology in a model of early Alzheimer\u2019s disease. Neuron 73:685\u2013697. https:\/\/doi.org\/10.1016\/j.neuron.2011.11.033","journal-title":"Neuron"},{"key":"12578_CR60","doi-asserted-by":"publisher","first-page":"e31302","DOI":"10.1371\/journal.pone.0031302","volume":"7","author":"L Liu","year":"2012","unstructured":"Liu L, Drouet V, Wu JW et al (2012) Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7:e31302. https:\/\/doi.org\/10.1371\/journal.pone.0031302","journal-title":"PLoS ONE"},{"key":"12578_CR61","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/alzrt214","volume":"5","author":"AM Pooler","year":"2013","unstructured":"Pooler AM, Polydoro M, Wegmann S, Pitstick R, Kay KR, Sanchez L, Mandelkow EM, Hyman BT, Spires-Jones TL (2013) Propagation of tau pathology in Alzheimer\u2019s disease: identification of novel therapeutic targets. Alzheimers Res Ther 5:49. https:\/\/doi.org\/10.1186\/alzrt214","journal-title":"Alzheimers Res Ther"},{"key":"12578_CR62","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.stem.2020.06.013","volume":"27","author":"R van der Kant","year":"2020","unstructured":"van der Kant R, Langness VF, Herrera CM et al (2020) Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-beta in iPSC-derived Alzheimer\u2019s disease neurons. Cell Stem Cell 27:75\u201391e9. https:\/\/doi.org\/10.1016\/j.stem.2020.06.013","journal-title":"Cell Stem Cell"},{"key":"12578_CR63","doi-asserted-by":"publisher","first-page":"786353","DOI":"10.3389\/fneur.2021.786353","volume":"12","author":"L Li","year":"2022","unstructured":"Li L, Jiang Y, Wang JZ, Liu R, Wang X (2022) Tau ubiquitination in Alzheimer\u2019s disease. Front Neurol 12:786353. https:\/\/doi.org\/10.3389\/fneur.2021.786353","journal-title":"Front Neurol"},{"key":"12578_CR64","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41593-018-0332-9","volume":"22","author":"EF Fang","year":"2019","unstructured":"Fang EF, Hou Y, Palikaras K et al (2019) Mitophagy inhibits amyloid-beta and tau pathology and reverses cognitive deficits in models of Alzheimer\u2019s disease. Nat Neurosci 22:401\u2013412. https:\/\/doi.org\/10.1038\/s41593-018-0332-9","journal-title":"Nat Neurosci"},{"key":"12578_CR65","doi-asserted-by":"publisher","first-page":"105342","DOI":"10.1016\/j.neuint.2022.105342","volume":"157","author":"QY Yu","year":"2022","unstructured":"Yu QY, Ye L, Li HL (2022) Molecular interaction of stress granules with Tau and autophagy in Alzheimer\u2019s disease. Neurochem Int 157:105342. https:\/\/doi.org\/10.1016\/j.neuint.2022.105342","journal-title":"Neurochem Int"},{"key":"12578_CR66","doi-asserted-by":"publisher","first-page":"e2014188118","DOI":"10.1073\/pnas.2014188118","volume":"118","author":"PEA Ash","year":"2021","unstructured":"Ash PEA, Lei S, Shattuck JE et al (2021) TIA1 potentiates tau phase separation and promotes generation of toxic oligomeric tau. Proc Natl Acad Sci U S A 118:e2014188118. https:\/\/doi.org\/10.1073\/pnas.2014188118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12578_CR67","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","volume":"21","author":"E Karran","year":"2022","unstructured":"Karran E, De Strooper B (2022) The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov 21:306\u2013318. https:\/\/doi.org\/10.1038\/s41573-022-00391-w","journal-title":"Nat Rev Drug Discov"},{"key":"12578_CR68","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi Y, Yamada K, Liddelow SA et al (2017) ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549:523\u2013527. https:\/\/doi.org\/10.1038\/nature24016","journal-title":"Nature"},{"key":"12578_CR69","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/mp.2013.1","volume":"18","author":"J Chapuis","year":"2013","unstructured":"Chapuis J, Hansmannel F, Gistelinck M et al (2013) Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Mol Psychiatry 18:1225\u20131234. https:\/\/doi.org\/10.1038\/mp.2013.1","journal-title":"Mol Psychiatry"},{"key":"12578_CR70","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1016\/j.celrep.2016.02.026","volume":"14","author":"P De Rossi","year":"2016","unstructured":"De Rossi P, Nomura T, Andrew RJ et al (2016) Neuronal BIN1 regulates presynaptic neurotransmitter release and memory consolidation. Cell Rep 14:2679\u20132690. https:\/\/doi.org\/10.1016\/j.celrep.2016.02.026","journal-title":"Cell Rep"},{"key":"12578_CR71","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/ng.803","volume":"43","author":"P Hollingworth","year":"2011","unstructured":"Hollingworth P, Harold D, Sims R et al (2011) Common variants at ABCA7, MS4A6A\/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer\u2019s disease. Nat Genet 43:429\u2013435. https:\/\/doi.org\/10.1038\/ng.803","journal-title":"Nat Genet"},{"key":"12578_CR72","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41593-018-0298-7","volume":"22","author":"H Fu","year":"2019","unstructured":"Fu H, Possenti A, Freer R et al (2019) A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology. Nat Neurosci 22:47\u201356. https:\/\/doi.org\/10.1038\/s41593-018-0298-7","journal-title":"Nat Neurosci"},{"key":"12578_CR73","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro R, Wojtas A, Bras J et al (2013) TREM2 variants in Alzheimer\u2019s disease. N Engl J Med 368:117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa1211851","journal-title":"N Engl J Med"},{"key":"12578_CR74","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson T, Stefansson H, Steinberg S et al (2013) Variant of TREM2 associated with the risk of Alzheimer\u2019s disease. N Engl J Med 368:107\u2013116. https:\/\/doi.org\/10.1056\/NEJMoa1211103","journal-title":"N Engl J Med"},{"key":"12578_CR75","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.neuron.2017.02.042","volume":"94","author":"JD Ulrich","year":"2018","unstructured":"Ulrich JD, Ulland TK, Colonna M, Holtzman DM (2018) Elucidating the role of TREM2 in Alzheimer\u2019s disease. Neuron 94:237\u2013248. https:\/\/doi.org\/10.1016\/j.neuron.2017.02.042","journal-title":"Neuron"},{"key":"12578_CR76","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13024-021-00465-9","volume":"16","author":"M Gratuze","year":"2021","unstructured":"Gratuze M, Leyns CEG, Holtzman DM (2021) New insights into the role of TREM2 in Alzheimer\u2019s disease. Mol Neurodegener 16:46. https:\/\/doi.org\/10.1186\/s13024-021-00465-9","journal-title":"Mol Neurodegener"},{"key":"12578_CR77","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41593-018-0291-1","volume":"22","author":"HU Klein","year":"2019","unstructured":"Klein HU, McCabe C, Gjoneska E et al (2019) Epigenome-wide study uncovers large-scale changes in histone acetylation driven by tau pathology in aging and Alzheimer human brain. Nat Neurosci 22:37\u201346. https:\/\/doi.org\/10.1038\/s41593-018-0291-1","journal-title":"Nat Neurosci"},{"key":"12578_CR78","doi-asserted-by":"publisher","first-page":"6721","DOI":"10.1093\/hmg\/ddv377","volume":"24","author":"PY Smith","year":"2015","unstructured":"Smith PY, Hernandez-Rapp J, Jolivette F et al (2015) miR-132\/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo. Hum Mol Genet 24:6721\u20136735. https:\/\/doi.org\/10.1093\/hmg\/ddv377","journal-title":"Hum Mol Genet"},{"key":"12578_CR79","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fphys.2015.00040","volume":"6","author":"GD Femminella","year":"2015","unstructured":"Femminella GD, Ferrara N, Rengo G (2015) The emerging role of microRNAs in Alzheimer\u2019s disease. Front Physiol 6:40. https:\/\/doi.org\/10.3389\/fphys.2015.00040","journal-title":"Front Physiol"},{"key":"12578_CR80","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13024-017-0192-x","volume":"12","author":"CEG Leyns","year":"2017","unstructured":"Leyns CEG, Holtzman DM (2017) Glial contributions to neurodegeneration in tauopathies. Mol Neurodegener 12:50. https:\/\/doi.org\/10.1186\/s13024-017-0192-x","journal-title":"Mol Neurodegener"},{"key":"12578_CR81","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J et al (2015) Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol 14:388\u2013405. https:\/\/doi.org\/10.1016\/S1474-4422(15)70016-5","journal-title":"Lancet Neurol"},{"key":"12578_CR82","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","volume":"4","author":"JW Kinney","year":"2018","unstructured":"Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT (2018) Inflammation as a central mechanism in Alzheimer\u2019s disease. Alzheimers Dement (N Y) 4:575\u2013590. https:\/\/doi.org\/10.1016\/j.trci.2018.06.014","journal-title":"Alzheimers Dement (N Y)"},{"key":"12578_CR83","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","volume":"19","author":"EE Congdon","year":"2023","unstructured":"Congdon EE, Sigurdsson EM (2023) Tau-targeting therapies for Alzheimer disease: current status and future directions. Nat Rev Neurol 19:715\u2013736. https:\/\/doi.org\/10.1038\/s41582-023-00883-2","journal-title":"Nat Rev Neurol"},{"key":"12578_CR84","doi-asserted-by":"publisher","first-page":"1053680","DOI":"10.3389\/fphar.2023.1053680","volume":"14","author":"MA Kamaruzzaman","year":"2023","unstructured":"Kamaruzzaman MA, Romli MH, Abas R, Vidyadaran S, Hidayat Baharuldin MT, Nasaruddin ML, Thirupathirao V, Sura S, Warsito K, Mohd Nor NH, Azwaruddin MA, Alshawsh MA, Mohd Moklas MA (2023) Regulatory role of the endocannabinoid system on glial cells toward cognitive function in Alzheimer\u2019s disease: a systematic review and meta-analysis of animal studies. Front Pharmacol 14:1053680. https:\/\/doi.org\/10.3389\/fphar.2023.1053680","journal-title":"Front Pharmacol"},{"key":"12578_CR85","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s12031-022-02047-1","volume":"72","author":"J Wojcieszak","year":"2022","unstructured":"Wojcieszak J, Kuczynska K, Zawilska JB (2022) Role of chemokines in the development and progression of Alzheimer\u2019s disease. J Mol Neurosci 72:1929\u20131951. https:\/\/doi.org\/10.1007\/s12031-022-02047-1","journal-title":"J Mol Neurosci"},{"key":"12578_CR86","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","volume":"575","author":"C Ising","year":"2019","unstructured":"Ising C, Venegas C, Zhang S et al (2019) NLRP3 inflammasome activation drives tau pathology. Nature 575:669\u2013673. https:\/\/doi.org\/10.1038\/s41586-019-1769-z","journal-title":"Nature"},{"key":"12578_CR87","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10571-026-01671-4","volume":"46","author":"PK Gopalakrishna","year":"2026","unstructured":"Gopalakrishna PK, Che Mohd Nassir CMN, Anandan S, Hussan F, Dandala KCR, Sura S, Jagadeesan S, Mohd Moklas MAM, Vishnumukkala T, Hein ZM (2026) The immuno-glial connectome in Alzheimer\u2019s disease: integrating central and peripheral inflammatory networks. Cell Mol Neurobiol 46:31. https:\/\/doi.org\/10.1007\/s10571-026-01671-4","journal-title":"Cell Mol Neurobiol"},{"key":"12578_CR88","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","volume":"25","author":"DA Nation","year":"2019","unstructured":"Nation DA, Sweeney MD, Montagne A et al (2019) Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med 25:270\u2013276. https:\/\/doi.org\/10.1038\/s41591-018-0297-y","journal-title":"Nat Med"},{"key":"12578_CR89","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","volume":"581","author":"A Montagne","year":"2020","unstructured":"Montagne A, Nation DA, Sagare AP et al (2020) APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature 581:71\u201376. https:\/\/doi.org\/10.1038\/s41586-020-2247-3","journal-title":"Nature"},{"key":"12578_CR90","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13024-026-00928-2","volume":"21","author":"KA Pareja-Navarro","year":"2026","unstructured":"Pareja-Navarro KA, King CD, Kauwe G et al (2026) Tau oligomers modulate synapse fate by eliciting progressive bipartite synapse dysregulation and synapse loss. Mol Neurodegener 21:13. https:\/\/doi.org\/10.1186\/s13024-026-00928-2","journal-title":"Mol Neurodegener"},{"key":"12578_CR91","doi-asserted-by":"publisher","first-page":"eaag0481","DOI":"10.1126\/scitranslmed.aag0481","volume":"9","author":"SL DeVos","year":"2017","unstructured":"DeVos SL, Miller RL, Schoch KM et al (2017) Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med 9:eaag0481. https:\/\/doi.org\/10.1126\/scitranslmed.aag0481","journal-title":"Sci Transl Med"},{"key":"12578_CR92","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G et al (2024) Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol 81:255\u2013263. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319","journal-title":"JAMA Neurol"},{"key":"12578_CR93","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/joim.12816","volume":"284","author":"K Blennow","year":"2018","unstructured":"Blennow K, Zetterberg H (2018) Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future. J Intern Med 284:643\u2013663. https:\/\/doi.org\/10.1111\/joim.12816","journal-title":"J Intern Med"},{"key":"12578_CR94","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/s41591-025-03622-w","volume":"31","author":"S Palmqvist","year":"2025","unstructured":"Palmqvist S, Warmenhoven N, Anastasi F et al (2025) Plasma phospho-tau217 for Alzheimer\u2019s disease diagnosis in primary and secondary care using a fully automated platform. Nat Med 31:2036\u20132043. https:\/\/doi.org\/10.1038\/s41591-025-03622-w","journal-title":"Nat Med"},{"key":"12578_CR95","doi-asserted-by":"publisher","first-page":"105405","DOI":"10.1016\/j.ebiom.2024.105405","volume":"109","author":"A Feizpour","year":"2024","unstructured":"Feizpour A, Ashton NJ, Karikari TK et al (2024) Detection and staging of Alzheimer\u2019s disease by plasma pTau217 on a high throughput immunoassay platform. EBioMedicine 109:105405. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105405","journal-title":"EBioMedicine"},{"key":"12578_CR96","doi-asserted-by":"publisher","first-page":"105046","DOI":"10.1016\/j.ebiom.2024.105046","volume":"102","author":"J Therriault","year":"2024","unstructured":"Therriault J, Ashton NJ, Pola I et al (2024) Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer\u2019s pathology. EBioMedicine 102:105046. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105046","journal-title":"EBioMedicine"},{"key":"12578_CR97","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1038\/s41467-024-46876-7","volume":"15","author":"PR Kac","year":"2024","unstructured":"Kac PR, Gonzalez-Ortiz F, Emersic A et al (2024) Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer\u2019s disease neuropathology. Nat Commun 15:2615. https:\/\/doi.org\/10.1038\/s41467-024-46876-7","journal-title":"Nat Commun"},{"key":"12578_CR98","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/S1474-4422(25)00227-3","volume":"24","author":"J Therriault","year":"2025","unstructured":"Therriault J, Brum W, Trudel L et al (2025) Blood phosphorylated tau for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol 24:740\u2013752. https:\/\/doi.org\/10.1016\/S1474-4422(25)00227-3","journal-title":"Lancet Neurol"},{"key":"12578_CR99","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson KA, Schultz A, Betensky RA et al (2016) Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 79:110\u2013119. https:\/\/doi.org\/10.1002\/ana.24546","journal-title":"Ann Neurol"},{"key":"12578_CR100","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Scholl","year":"2016","unstructured":"Scholl M, Lockhart SN, Schonhaut DR et al (2016) PET imaging of tau deposition in the aging human brain. Neuron 89:971\u2013982. https:\/\/doi.org\/10.1016\/j.neuron.2016.01.028","journal-title":"Neuron"},{"key":"12578_CR101","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S1474-4422(14)70252-2","volume":"14","author":"VL Villemagne","year":"2015","unstructured":"Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC (2015) Tau imaging: early progress and future directions. Lancet Neurol 14:114\u2013124. https:\/\/doi.org\/10.1016\/S1474-4422(14)70252-2","journal-title":"Lancet Neurol"},{"key":"12578_CR102","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Scholl M et al (2016) Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain 139:1551\u20131567. https:\/\/doi.org\/10.1093\/brain\/aww027","journal-title":"Brain"},{"key":"12578_CR103","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ et al (2020) Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 19:422\u2013433. https:\/\/doi.org\/10.1016\/S1474-4422(20)30071-5","journal-title":"Lancet Neurol"},{"key":"12578_CR104","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S et al (2020) Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med 26:379\u2013386. https:\/\/doi.org\/10.1038\/s41591-020-0755-1","journal-title":"Nat Med"},{"key":"12578_CR105","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT et al (2020) Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324:772\u2013781. https:\/\/doi.org\/10.1001\/jama.2020.12134","journal-title":"JAMA"},{"key":"12578_CR106","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","volume":"17","author":"H Hampel","year":"2021","unstructured":"Hampel H, Cummings J, Blennow K et al (2021) Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol 17:580\u2013589. https:\/\/doi.org\/10.1038\/s41582-021-00520-w","journal-title":"Nat Rev Neurol"},{"key":"12578_CR107","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O (2021) Biomarkers for neurodegenerative diseases. Nat Med 27:954\u2013963. https:\/\/doi.org\/10.1038\/s41591-021-01382-x","journal-title":"Nat Med"},{"key":"12578_CR108","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH et al (2022) Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol 21:66\u201377. https:\/\/doi.org\/10.1016\/S1474-4422(21)00361-6","journal-title":"Lancet Neurol"},{"issue":"Suppl 5","key":"12578_CR109","doi-asserted-by":"publisher","first-page":"e099279","DOI":"10.1002\/alz70859_099279","volume":"21","author":"RP Maguire","year":"2025","unstructured":"Maguire RP, Byrnes W, Barton ME et al (2025) Tau positron emission tomography results from TOGETHER, a double-blind, placebo-controlled Phase II study of bepranemab in prodromal-mild Alzheimer\u2019s disease. Alzheimers Dement 21(Suppl 5):e099279. https:\/\/doi.org\/10.1002\/alz70859_099279","journal-title":"Alzheimers Dement"},{"key":"12578_CR110","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","volume":"29","author":"CJ Mummery","year":"2023","unstructured":"Mummery CJ, Borjesson-Hanson A, Blackburn DJ et al (2023) Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer\u2019s disease: a phase 1b, randomized, placebo-controlled trial. Nat Med 29:1437\u20131447. https:\/\/doi.org\/10.1038\/s41591-023-02326-3","journal-title":"Nat Med"},{"key":"12578_CR111","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jamaneurol.2023.3861","volume":"80","author":"AL Edwards","year":"2023","unstructured":"Edwards AL, Collins JA, Junge C et al (2023) Exploratory tau biomarker results from a multiple ascending-dose study of BIIB080 in Alzheimer disease: a randomized clinical trial. JAMA Neurol 80:1344\u20131352. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3861","journal-title":"JAMA Neurol"},{"key":"12578_CR112","doi-asserted-by":"publisher","first-page":"eabe1611","DOI":"10.1126\/sciadv.abe1611","volume":"7","author":"S Wegmann","year":"2021","unstructured":"Wegmann S, DeVos SL, Zeitler B et al (2021) Persistent repression of tau in the brain using engineered zinc finger protein transcription factors. Sci Adv 7:eabe1611. https:\/\/doi.org\/10.1126\/sciadv.abe1611","journal-title":"Sci Adv"},{"key":"12578_CR113","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.1016\/j.ymthe.2025.08.052","volume":"33","author":"JM Hogestyn","year":"2025","unstructured":"Hogestyn JM, Wischhof E, Chen Y, Chan T, Richards B, Mahendran T, Adams J, Dubreuil D, Bu J, Jackson R, Goulet M, Mueller C, Ramachandran S, Elmer B (2025) AAV delivery of artificial miRNA targeting MAPT for the reduction of tau pathology in Alzheimer\u2019s disease. Mol Ther 33:6298\u20136313. https:\/\/doi.org\/10.1016\/j.ymthe.2025.08.052","journal-title":"Mol Ther"},{"key":"12578_CR114","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3233\/JAD-142874","volume":"44","author":"CM Wischik","year":"2015","unstructured":"Wischik CM, Staff RT, Wischik DJ et al (2015) Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer\u2019s disease. J Alzheimers Dis 44:705\u2013720. https:\/\/doi.org\/10.3233\/JAD-142874","journal-title":"J Alzheimers Dis"},{"key":"12578_CR115","doi-asserted-by":"publisher","first-page":"89","DOI":"10.22452\/mjs.vol44sp1.14","volume":"44","author":"S Sura","year":"2025","unstructured":"Sura S, Vishnumukkala T, Masrudin SS, Mohd Moklas MA, Kamaruzzaman MA, Dandala KCR, Gandrakota R, Mohd Nor NH (2025) Therapeutic potential of cannabidiol in alleviating cognitive decline and hippocampal damage in a rat model of Alzheimer\u2019s disease. Malays J Sci 44:89\u201396. https:\/\/doi.org\/10.22452\/mjs.vol44sp1.14","journal-title":"Malays J Sci"},{"key":"12578_CR116","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM (2022) PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov 21:181\u2013200. https:\/\/doi.org\/10.1038\/s41573-021-00371-6","journal-title":"Nat Rev Drug Discov"},{"key":"12578_CR117","doi-asserted-by":"publisher","first-page":"1351792","DOI":"10.3389\/fphar.2024.1351792","volume":"15","author":"D Yao","year":"2024","unstructured":"Yao D, Li T, Yu L, Hu M, He Y, Zhang R, Wu J, Li S, Kuang W, Yang X, Liu G, Xie Y (2024) Selective degradation of hyperphosphorylated tau by proteolysis-targeting chimeras ameliorates cognitive function in Alzheimer\u2019s disease model mice. Front Pharmacol 15:1351792. https:\/\/doi.org\/10.3389\/fphar.2024.1351792","journal-title":"Front Pharmacol"},{"key":"12578_CR118","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/bs.pmbts.2025.07.011","volume":"210","author":"S Chinnathambi","year":"2025","unstructured":"Chinnathambi S (2025) Tau proteostasis in Alzheimer\u2019s disease. Prog Mol Biol Transl Sci 210:177\u2013207. https:\/\/doi.org\/10.1016\/bs.pmbts.2025.07.011","journal-title":"Prog Mol Biol Transl Sci"},{"key":"12578_CR119","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cstres.2024.11.006","volume":"29","author":"X Jeanne","year":"2024","unstructured":"Jeanne X, T\u00f6r\u00f6k Z, Vigh L, Prodromou C (2024) The role of the FKBP51-Hsp90 complex in Alzheimer\u2019s disease: an emerging new drug target. Cell Stress Chaperones 29:792\u2013804. https:\/\/doi.org\/10.1016\/j.cstres.2024.11.006","journal-title":"Cell Stress Chaperones"},{"key":"12578_CR120","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.neuron.2020.06.004","volume":"106","author":"H Zetterberg","year":"2020","unstructured":"Zetterberg H, Blennow K (2020) Blood biomarkers: democratizing Alzheimer\u2019s diagnostics. Neuron 106:881\u2013883. https:\/\/doi.org\/10.1016\/j.neuron.2020.06.004","journal-title":"Neuron"},{"key":"12578_CR121","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","volume":"28","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele R, Pichet Binette A, Groot C et al (2022) Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med 28:2381\u20132387. https:\/\/doi.org\/10.1038\/s41591-022-02049-x","journal-title":"Nat Med"},{"key":"12578_CR122","doi-asserted-by":"publisher","first-page":"39","DOI":"10.26538\/tjnpr\/v10i3.39","volume":"10","author":"S Sura","year":"2026","unstructured":"Sura S, Vishnumukkala T, Okwuofu EO, Gopalakrishna PK, Jagadeesan S, Dandala KCR, Aris MMM, Masrudin SS, Huda NMN (2026) Cannabidiol from Cannabis sativa: a potential therapeutic agent for neurodegenerative diseases. Trop J Nat Prod Res 10:39. https:\/\/doi.org\/10.26538\/tjnpr\/v10i3.39","journal-title":"Trop J Nat Prod Res"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12578-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12578-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12578-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T13:25:04Z","timestamp":1786627504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12578-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":122,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12578"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12578-0","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"27 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1396"}}